Research and Markets: Chugai Pharmaceutical Company Report Provides A Full Review Of The Company's Activities Together With Five Year Sales Forecasts For Its Key Products

Business Wire, August 2, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c64666) has announced the addition of "Chugai: Performance, Products, Pipeline and Potential" to their offering.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Chugai Pharmaceuticals is a research-driven, pure-play pharmaceutical company, headquartered in Japan. As a member of the Roche Group since October 2002, it has rights to develop and market all pharmaceutical products which the Roche Group decides to commercialise in Japan, and Roche has the right to license-in all Chugai products outside of Japan and South Korea for which Chugai seeks a partner. Chugai maintains all the functions of research, development, production and marketing, as well as retaining management autonomy. The company has now positioned oncology as a key strategic sector along with renal diseases, and bones and joints.

Market conditions in Japan are becoming increasingly fierce. Japan's medical insurance system is being reformed, with measures being taken to curb medical expenses, including the promotion of generic drug use and the April 2004 national health insurance drug price revisions. In addition, these developments are occurring against a backdrop of rapid demographic change, with a falling birth rate and increasing numbers of aged citizens, and the possibility of further drug price reform.

Now a pure-play prescription pharmaceuticals company, Chugai is well equipped to face these challenges as a member of the Roche Group. Reflecting the power of a combined Chugai/Roche pipeline, in 2006 it filed for eight products, five of which have been developed as the principal growth drivers for the company into 2010. However, products filed in 2006 will only start to make a major contribution to sales around 2008 or later and sales in 2006 remained more or less static, with both operating and net income down from the previous year. In addition, since worldwide trends towards medical cost reductions will continue, the business environment for Chugai will remain challenging into 2007.

This new strategic analysis report Chugai: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

Contents:

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting

Oncology

Avastin (bevacizumab)

Femara (letrozole)

Furtulon (doxifluridine)

Herceptin (trastuzumab)

Kytril (granisetron)

Neutrogin/ Granocyte (lenograstim)

Rituxan (rituximab)

Xeloda (capecitabine)

Renal Diseases

Epogin (EPOCH; epoetin beta)

Oxarol (maxacalcitol)

Pletal/Pletaal (cilostazol)

Renagel (sevelamer)

Transplant, Immunology and Infectious Diseases

Actemra (tocilizumab)

CellCept (mycophenolate mofetil)

Invirase (saquinavir)

Pegasys (pegylated-40K interferon alpha-2a)

Rocephin (ceftriaxone)

Tamiflu (oseltamivir)

Bone and Joint

Alfarol (alfacalcidol)

Evista (raloxifene)

Suvenyl (sodium hyaluronate)

Cardio/Cerebro-Vascular

Rythmodan (disopyramide)

Sigmart/Ikorel (nicorandil)

OPERATIONAL DATA

A wealth of background and detail

A full 5-year financial performance assessment

Key corporate events

Key agreements

Infrastructure

Subsidiaries

For more information visit http://www.researchandmarkets.com/reports/c64666

Source: Espicom